

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**中國動物保健品有限公司\***

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 0940)**

## **APPOINTMENT OF EXECUTIVE DIRECTOR**

The board of directors (the “**Board**”) of China Animal Healthcare Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Mr. Wang Yongwei (“**Mr. Wang**”) has been appointed as an executive director of the Company with effect from 11 September 2017.

Mr. Wang, aged 33, obtained a Bachelor’s degree in biomedical engineering from Hebei University of Technology in 2008. Mr. Wang worked for Ji Lin Hui Rui Guo Yuan Dong Wu Bao Jian Pin Limited (吉林輝瑞國原動物保健品有限公司) as a vice general manager from September 2009 to February 2013. Mr. Wang joined the Group in March 2013 and was serving as the deputy general manager of Inner Mongolia Bigvet Biotech Co., Ltd (“**Inner Mongolia Bigvet Biotech**”), a subsidiary of the Company, during March 2013 to December 2015. Mr. Wang is currently the general manager of Inner Mongolia Bigvet Biotech.

Mr. Wang entered into a service agreement with the Company on 11 September 2017 for an initial term of 1 year, which may be terminated by either party by giving three months’ written notice. Mr. Wang’s appointment will be subject to normal retirement and re-election pursuant to the bye-laws of the Company and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). Mr. Wang will be entitled to a director’s remuneration of HK\$150,000 per annum, which was determined by the Board and its delegated committee with reference to the duties, responsibilities and work performance of Mr. Wang, as well as the prevailing market conditions.

As at the date of this announcement, Mr. Wang has personal interests in 298,000 shares of the Company, representing approximately 0.015% interests in the share capital of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Mr. Wang does not have any relationship with any directors, senior management, substantial or

controlling shareholders of the Company. Mr. Wang confirms that he has not held other directorships in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years.

Save as disclosed above, there is no other information relating to Mr. Wang that is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and there are no other matters relating to the appointment of Mr. Wang that need to be brought to the attention of the shareholders of the Company.

The Board would like to welcome Mr. Wang for joining as a member of the Board.

#### **CONTINUAL SUSPENSION OF TRADING**

At the request of the Company, the shares of the Company have been suspended from trading on the Stock Exchange from 9 a.m. on 30 March 2015. Trading in the Company's shares will continue to suspend until further notice.

**Shareholders and potential investors are advised to exercise caution when dealing in the Shares.**

**By Order of the Board**  
**China Animal Healthcare Ltd.**  
**Song Yanmei**  
*Chairman and Executive Director*

Hong Kong, 11 September 2017

*As at the date of announcement, the executive Director is Ms. Song Yanmei and Mr. Wang Yongwei; and the independent non-executive Directors are Mr. Cai Huiyi, Mr. Liu Zhanmin and Mr. Zhang Suqiang.*

*\* for identification purpose only*